LAUSR

of high-dose activated factor VII. Blood Coagul Fibrinolysis. 1998;9(suppl 1):S61–S65. 6. Turecek PL, Varadi K, Gritsch H et al. FEIBAs: mode of action. Haemophilia. 2004;10(suppl 2):3–9. 7. Shapiro AD, Hedner U. Advances in bypassing agent therapy for hemophilia patients with inhibitors to close care gaps and improve outcomes. Ther Adv Drug Saf. 2011;2:213–225. 8. Konkle BA, Ebbesen LS, Erhardtsen E, et al. Randomized, prospective clinical trial of recombinant factor VIIa for secondary prophylaxis in hemophilia patients with inhibitors. Jthromb Haemost. 2007;5:1904–1913. 9. Hoots WK, Ebbesen LS, Konkle BA, et al. Secondary prophylaxis with recombinant activated factor VII improves health-related quality of life of haemophilia patients with inhibitors. Haemophilia. 2008;14:466–475. 10. Warrier I, Ewenstein B, Koerper MA et al. Factor IX inhibitors and anaphylaxis in hemophilia B. J Pediatr Hematol Oncol. 1997;19:23–27. 11. Thorland EC, Drost JB, Lusher JM et al. Anaphylactic response to factor IX replacement therapy in haemophilia B patients: complete gene deletions confer the highest risk. Haemophilia. 1999;5:101–105. 12. Lusher JM. Inhibitor antibodies to factor VIII and factor IX: management. Semin Thromb Hemostat. 2000;26:179–188.